ArticleMolecular imaging and biology2015

Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.

Marco Baron Toaldo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.